Clinical trials: Body Weight Control
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Overweight , Obesity
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants.
- Trial name
- NCT07791537
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone
This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and…
- Trial name
- MILEPOST (NCT01843231)
- Testing
- g-CathTM EZ Suture Anchor Delivery Catheter, Diet and Exercise Control Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 40 people
- Sponsor
- USGI Medical
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Obesity
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with obesity. This study includes three multiple-ascending dose cohorts.
- Trial name
- NCT06951945
- Testing
- THDBH120 injection
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Menopause Related Conditions
ProGo Menopause Wellbeing Study
This study will evaluate whether ProGo®, a salmon protein hydrolysate (SPH), helps to moderate body mass index (BMI) and improve quality of life (QoL) in menopausal women.
- Trial name
- NCT07611305
- Testing
- Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hofseth Biocare ASA
Overweight, Type 2 Diabetes
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Trial name
- NCT06926842
- Testing
- Petrelintide
- Where
- 48 sites in United States
- Volunteers
- 221 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes Mellitus (T2DM), Obesity and Overweight
CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes
The goal of this clinical trial is to learn if treatment with CK-0045 improves blood sugar control after a meal in participants with type 2 diabetes mellitus (T2DM) and overweight/obesity.
- Trial name
- NCT06611930
- Testing
- CK-0045
- Where
- 2 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Cytoki Pharma
Obese, Obesity
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
- Trial name
- NCT07205900
- Testing
- HM15275
- Where
- 14 sites in United States
- Volunteers
- 267 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Weight Management, Treatment Of Obesity
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes
- Trial name
- NCT00542009
- Testing
- CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Obesity, Overweight
A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.
- Trial name
- NCT01540864
- Testing
- HPP404
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- High Point Pharmaceuticals, LLC.
Obesity
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity
The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
- Trial name
- NCT00364871
- Testing
- naltrexone and bupropion SR
- Where
- 7 sites in United States
- Volunteers
- 410 people
- Sponsor
- Orexigen Therapeutics, Inc
Diabetes Mellitus, Type 2 DM
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management…
- Trial name
- GLYCO-3P (NCT06862739)
- Testing
- Empagliflozin+Linagliptin+Metformin
- Where
- 2 sites in Pakistan
- Volunteers
- 800 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Obesity
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
- Trial name
- NCT06893016
- Testing
- RAY1225
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Obesity, Diabetes Mellitus, Type 2
A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin
The purpose of this study is to evaluate the effectiveness and safety of a topiramate controlled-release formulation in the treatment of obese, type 2 diabetic patients managed with diet alone or combined with metformin.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231647
- Testing
- topiramate
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alcohol Use Disorder (AUD)
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight.
- Trial name
- NCT06987513
- Testing
- Pemvidutide
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Altimmune, Inc.
Obesity
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.
- Trial name
- NCT00092859
- Testing
- MK0557
- Volunteers
- 1,500 people
- Sponsor
- Merck Sharp & Dohme LLC
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
- Trial name
- NCT03205150
- Testing
- LIK066
- Where
- 15 sites in United States, Argentina and 6 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals